Oral Solid Dosage Forms (OSDF) and Pharma Excipients

Oral Solid Dosage Forms (OSDF) and Pharma Excipients

Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market to Reach US$1.8 Billion by 2030

The global market for Oral Solid Dosage Forms (OSDF) and Pharma Excipients estimated at US$1.3 Billion in the year 2023, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Polymers, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$932.4 Million by the end of the analysis period. Growth in the Alcohols segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$341.3 Million While China is Forecast to Grow at 4.7% CAGR

The Oral Solid Dosage Forms (OSDF) and Pharma Excipients market in the U.S. is estimated at US$341.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$280.7 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market - Key Trends & Drivers Summarized

Why Are Oral Solid Dosage Forms Dominant in Pharmaceutical Delivery?

Oral Solid Dosage Forms (OSDF), such as tablets and capsules, remain the most common and preferred method of drug delivery in the pharmaceutical industry due to their convenience, stability, and cost-effectiveness. OSDFs are favored by both healthcare providers and patients for their ease of administration and ability to deliver precise doses of medication. These forms also offer greater stability than liquid formulations, with longer shelf lives and better storage conditions, making them ideal for global distribution. With continuous advancements in drug formulation, oral solid dosage forms can now deliver complex drug compounds, including controlled-release and targeted drug delivery systems, offering enhanced therapeutic effects.

What Role Do Pharma Excipients Play in the Development of OSDFs?

Pharmaceutical excipients, which are inactive substances formulated alongside the active drug, play a crucial role in the development and performance of oral solid dosage forms. Excipients are essential in ensuring drug stability, improving bioavailability, and facilitating the manufacturing process. New excipients are being developed to address specific formulation challenges, such as improving the solubility of poorly water-soluble drugs or enabling sustained release mechanisms. Moreover, the rise of biologics and complex drug compounds is driving innovation in excipient technologies, as manufacturers seek novel solutions to ensure these advanced therapies can be effectively delivered in solid dosage form.

How Are Regulatory and Industry Trends Shaping the OSDF and Pharma Excipients Market?

The OSDF and pharma excipients market is closely regulated by global health authorities, ensuring that both the active drug and excipients meet stringent safety, efficacy, and quality standards. These regulations are driving manufacturers to invest in high-quality excipients and state-of-the-art manufacturing processes to ensure compliance with good manufacturing practices (GMP). Additionally, the rise of personalized medicine and the growing demand for patient-centric dosage forms are influencing the market, with a focus on developing tailored excipients and formulations that can accommodate specific patient needs, such as pediatric or geriatric populations. Sustainability is also becoming a key consideration, with companies exploring environmentally friendly excipient alternatives.

The Growth in the OSDF and Pharma Excipients Market Is Driven by Several Factors

The growth in the oral solid dosage forms and pharma excipients market is driven by several factors, including the widespread preference for OSDFs due to their convenience, stability, and cost-effectiveness. Technological advancements in drug formulation and excipient development are enabling the creation of more sophisticated and effective drug delivery systems, including controlled-release and targeted therapies. Regulatory demands for high-quality, compliant excipients are also pushing innovation in this sector. Additionally, the rise of complex drug compounds, biologics, and personalized medicine is creating new opportunities for specialized excipients. Moreover, the increasing demand for sustainable and patient-centric dosage forms is further driving the development of novel excipient technologies.

Select Competitors (Total 46 Featured) -

• Abitec Corporation
• Akzo Nobel NV
• Archer Daniels Midland Company
• Associated British Foods PLC
• Avantor Performance Materials LLC
• BASF SE
• Cabot Corporation
• Cargill, Inc.
• Celanese Corporation
• Croda International PLC
• Dow, Inc.
• DuPont de Nemours, Inc.
• Eastman Chemical Company
• Ferro Corporation
• FMC Corporation
• FMC Corporation
• Huntsman Corporation
• Ingredion, Inc.
• Innophos Holdings, Inc.
• J.M. Huber Corporation
• Kuraray Co., Ltd.
• Medtronic PLC
• Merck KGaA
• Nitta Gelatin, Inc.
• Procter & Gamble Company, The
• Royal Dutch Shell PLC
• The Lubrizol Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.